-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Update
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Update
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 1,930,000 shares, a drop of 18.2% from the July 15th total of 2,360,000 shares. Based on an average daily volume of 335,800 shares, the short-interest ratio is currently 5.7 days.
Kiniksa Pharmaceuticals Trading Up 2.1 %
NASDAQ KNSA traded up $0.25 during trading hours on Friday, hitting $12.41. 404,852 shares of the company's stock were exchanged, compared to its average volume of 457,088. The stock has a 50-day simple moving average of $10.44 and a 200 day simple moving average of $10.09. Kiniksa Pharmaceuticals has a 1-year low of $7.36 and a 1-year high of $15.24.
Get Kiniksa Pharmaceuticals alerts:Institutional Investors Weigh In On Kiniksa Pharmaceuticals
Several large investors have recently added to or reduced their stakes in KNSA. Great Point Partners LLC grew its stake in Kiniksa Pharmaceuticals by 108.3% during the first quarter. Great Point Partners LLC now owns 1,118,067 shares of the company's stock worth $11,114,000 after purchasing an additional 581,329 shares during the period. Goldman Sachs Group Inc. grew its stake in Kiniksa Pharmaceuticals by 61.7% in the first quarter. Goldman Sachs Group Inc. now owns 936,604 shares of the company's stock valued at $9,310,000 after acquiring an additional 357,387 shares during the period. Renaissance Technologies LLC acquired a new stake in Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $3,570,000. Pictet Asset Management SA grew its stake in Kiniksa Pharmaceuticals by 6.4% in the fourth quarter. Pictet Asset Management SA now owns 3,548,649 shares of the company's stock valued at $41,768,000 after acquiring an additional 213,744 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Kiniksa Pharmaceuticals by 126.6% in the first quarter. Dimensional Fund Advisors LP now owns 360,940 shares of the company's stock valued at $3,588,000 after acquiring an additional 201,622 shares during the period. Institutional investors and hedge funds own 42.57% of the company's stock.
Kiniksa Pharmaceuticals Company Profile
(Get Rating)Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
See Also
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- MarketBeat: Week in Review 8/8 – 8/12
- 2 Important Retail Stock Battles to Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 1,930,000 shares, a drop of 18.2% from the July 15th total of 2,360,000 shares. Based on an average daily volume of 335,800 shares, the short-interest ratio is currently 5.7 days.
基尼克萨制药有限公司(纳斯达克代码:KNSA-GET评级)是空头股数7月份大幅下跌的目标。截至7月31日,空头股数共有193万股,与7月15日236万股的总数相比,下降了18.2%。以日均成交量33.58万股计算,目前短息比率为5.7天。
Kiniksa Pharmaceuticals Trading Up 2.1 %
Kiniksa制药公司股价上涨2.1%
NASDAQ KNSA traded up $0.25 during trading hours on Friday, hitting $12.41. 404,852 shares of the company's stock were exchanged, compared to its average volume of 457,088. The stock has a 50-day simple moving average of $10.44 and a 200 day simple moving average of $10.09. Kiniksa Pharmaceuticals has a 1-year low of $7.36 and a 1-year high of $15.24.
上周五,纳斯达克KNSA股价上涨0.25美元,至12.41美元。该公司股票成交量为404,852股,而其平均成交量为457,088股。该股的50日简单移动均线切入位10.44美元,200日简单移动均线切入位10.09美元。Kiniksa PharmPharmticals的一年低点为7.36美元,一年高位为15.24美元。
Institutional Investors Weigh In On Kiniksa Pharmaceuticals
机构投资者看好Kiniksa制药公司
Several large investors have recently added to or reduced their stakes in KNSA. Great Point Partners LLC grew its stake in Kiniksa Pharmaceuticals by 108.3% during the first quarter. Great Point Partners LLC now owns 1,118,067 shares of the company's stock worth $11,114,000 after purchasing an additional 581,329 shares during the period. Goldman Sachs Group Inc. grew its stake in Kiniksa Pharmaceuticals by 61.7% in the first quarter. Goldman Sachs Group Inc. now owns 936,604 shares of the company's stock valued at $9,310,000 after acquiring an additional 357,387 shares during the period. Renaissance Technologies LLC acquired a new stake in Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $3,570,000. Pictet Asset Management SA grew its stake in Kiniksa Pharmaceuticals by 6.4% in the fourth quarter. Pictet Asset Management SA now owns 3,548,649 shares of the company's stock valued at $41,768,000 after acquiring an additional 213,744 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Kiniksa Pharmaceuticals by 126.6% in the first quarter. Dimensional Fund Advisors LP now owns 360,940 shares of the company's stock valued at $3,588,000 after acquiring an additional 201,622 shares during the period. Institutional investors and hedge funds own 42.57% of the company's stock.
几家大型投资者最近增持或减持了KNSA的股份。第一季度,Great Point Partners LLC在Kiniksa制药公司的持股增加了108.3%。Great Point Partners LLC在此期间又购买了581,329股,现在拥有1,118,067股公司股票,价值11,114,000美元。高盛股份有限公司在第一季度增持了61.7%的基尼克萨制药股份。高盛股份有限公司在此期间增持了357,387股,目前持有该公司936,604股股票,价值9,310,000美元。复兴技术公司在第四季度收购了Kiniksa制药公司的新股份,价值约为357万美元。Pictet Asset Management SA在第四季度将其在Kiniksa PharmPharmticals的持股增加了6.4%。Pictet Asset Management SA现在拥有3548,649股该公司的股票,价值41,768,000美元,在此期间又收购了213,744股。最后,Dimension Fund Advisors LP在第一季度将其在Kiniksa制药公司的持股增加了126.6%。Dimension Fund Advisors LP在此期间额外收购了201,622股,现在拥有360,940股该公司的股票,价值3,588,000美元。机构投资者和对冲基金持有该公司42.57%的股票。
Kiniksa Pharmaceuticals Company Profile
Kiniksa制药公司简介
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Kiniksa制药有限公司是一家生物制药公司,专注于发现、获得、开发治疗药物,并将其商业化,用于治疗世界各地严重未得到满足的医疗需求的衰弱疾病患者。它的候选产品包括用于治疗复发性心包炎的ARCALYST,这是一种炎症性心血管疾病,是一种治疗复发性心包炎的药物;Mavrilimumab,一种完成了治疗巨细胞动脉炎的第二阶段临床试验的单抗;Vixarelimab,一种处于2a期临床试验的单抗,用于治疗慢性炎症性皮肤疾病结节性瘙痒;以及KPL-404,一种CD40-CD154相互作用的单抗抑制物,一种对B细胞成熟、免疫球蛋白类别转换和1型免疫反应至关重要的T细胞共刺激信号。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- MarketBeat: Week in Review 8/8 – 8/12
- 2 Important Retail Stock Battles to Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免费获取StockNews.com关于Kiniksa制药公司(KNSA)的研究报告
- MarketBeat:回顾中的一周2012-8-8
- 值得关注的两场重要的零售股大战
- 什么是WallStreetBets,他们的目标是什么股票?
- 机构和分析师推动Jack in the Box走高
- 你能猜到哪个电动车股票打败了特斯拉吗?
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Kiniksa制药日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Kiniksa制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧